胸腔病例（三九八）癌症患者瀰漫性肺病之處置

10.6666/ClinMed.202403_93(3).0034

柯宏叡；柯信國

肺囊蟲肺炎（pneumocystic pneumonia） ； 藥物相關間質性肺病（drug-induced pneumonitis, drug-related interstitial lung disease） ； 瀰漫性肺病（diffuse lung disease） ； trastuzumab deruxtecan（T-DXd, Enhertu）

臨床醫學月刊

93卷3期（2024 / 03 / 29）

185 - 189

繁體中文

在日新月異的抗癌治療年代，瀰漫性浸潤及間質性肺病在癌症患者是現代醫學一大診斷與治療的挑戰。個案為一中年女性，接受抗癌新藥時發生急性呼吸衰竭，原主要懷疑藥物性肺炎，在接受支氣管鏡肺泡沖洗後證實為肺囊蟲肺部感染。本文簡要介紹藥物性肺炎和肺囊蟲肺炎的臨床特徵、鑑別診斷與處置方式。

1. Wijsenbeek M, Suzuki A, Maher TM. Interstitial lung diseases. Lancet 2022;400:769-86.
   連結：
2. Ogitani Y, Aida T, Hagihara K, et al. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1. Clin Cancer Res 2016;22:5097-108.
   連結：
3. Cortés J, Kim SB, Chung WP, et al. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. N Engl J Med 2022;386:1143-54.
   連結：
4. Modi S, Jacot W, Yamashita T, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med 2022;387:9-20.
   連結：
5. Shitara K, Bang YJ, Iwasa S, Sugimoto N, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. N Engl J Med 2020;382:2419-30.
   連結：
6. Li BT, Smit EF, Goto Y, et al. Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med 2022;386:241-51.
   連結：
7. Siena S, Di Bartolomeo M, Raghav K, et al. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncol 2021;22:779-89.
   連結：
8. Modi S, Saura C, Yamashita T, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med 2020;382:610-21.
   連結：
9. Hamilton EP, Shapiro C, Petrylak D, et al. Trastuzumab deruxtecan (T-DXd; DS-8201) with nivolumab in patients with HER2-expressing, advanced breast cancer: a 2-part, phase 1b, multicenter, open-label study. Cancer Re 2021;81:PD3-PD07.
   連結：
10. Tarantino P, Modi S, Tolaney SM, et al. Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates: A Review. JAMA Oncol 2021;7:1873-81.
    連結：
11. Ponce CA, Gallo M, Bustamante R, et al. Pneumocystis colonization is highly prevalent in the autopsied lungs of the general population. Clin Infect Dis 2010;50:347-53.
    連結：
12. Onishi A, Sugiyama D, Kogata Y, et al. Diagnostic accuracy of serum 1,3-β-D-glucan for pneumocystis jiroveci pneumonia, invasive candidiasis, and invasive aspergillosis: systematic review and meta-analysis. J Clin Microbiol 2012;50:7-15.
    連結：
13. Kovacs JA, Hiemenz JW, Macher AM, et al. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med 1984;100:663-71.
    連結：
14. Chen PY, Yu CJ, Chien JY, et al. Anidulafungin as an alternative treatment for Pneumocystis jirovecii pneumonia in patients who cannot tolerate trimethoprim/sulfamethoxazole. Int J Antimicrob Agents 2020;55:105820.
    連結：
15. Swain SM, Nishino M, Lancaster LH, et al. Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and management. Cancer Treat Rev 2022;106:102378.
    連結：
16. Hurvitz SA, Hegg R, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet 2023;401:105-17.